AVM Biotechnology

The company's lead drug AVM0703, a proprietary innovative formulation of dexamethasone, when given at supra-pharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology was founded by Dr. Theresa Deisher with a personal mission to defeat cancer and has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.